NEWER VIRAL VACCINE ICLUDED RECENT ADVACES IN THE VACCINE DEVELOPMENT And as per WHO 2023 data pipeline vaccine detail like HIV, TB, DENGUE, HPV,FLU VACCINE AND ALSO EMPHASIS ON THE COVID VACCINE AND AS PER LATEST 2023 GOEVENMENT OF INDIA AND WORLD HEALTH ORGANISATION

1. NEWER VIRAL VACCINES
PRESENTER - DR. NAGENDRA KUMAR
JR2
PG DEPARTMENT OF MICROBIOLOGY
GMC JAMMU

2. Vaccination:
The process of inducing active immunity artificially by injecting a killed or an
attenuated microorganism or its component (an antigen) into a healthy
individual.
Aimed at inducing long-acting protective immunity in the form of antibody-
producing plasma cells, memory B cells, and memory T cells.

4. Commonly used viral vaccine:
LIVE ATTENUATED
VACCINE
KILLED OR INACTIVATED SUBUNIT VACCINE COMBINED VACCINE
MEASELES VACCINE INJECTABLE POLIO VACCINE HEPATITIS B VACCINE MMR VACCINE
MUMPS VACCINE KILLED INFLUENZA
VACCINE
HPV VACCINE
RUBELLA VACCINE RABIES VACCINE
INFLUENZA VACCINE Hep.A VACCINE
CHICKENPOX VACCINE JE VACCINE
ORAL POLIO VACCINE
ROTAVIRUS VACCINE
YELLOW FEVER 17D
VACCINE
Hep.A VACCINE,JE(14-14-2
STARIN) VACCINE

5. VIRAL VACCINE: DNA /RNA VACCINES
DNA VACCINE RNA VACCINE

6. Latest update:

11. Emerging and emerging viral diseases :

13. Viral Vaccine History:

14. vaccines developed and manufactured in India, along with their indications
in different diseases:
S.No Vaccines developed & manufactured in India Route of administration Indication/disease
1 iNCOVACC Intra nasal (drops) Corona virus
2 Covaxin Intramuscular injection in the deltoid
muscles of upper arm
Corona virus
3 ZyCoV-D Corona virus
4 CadiFlu-S Intramuscular injection (sterile liquid) Seasonal influenza
5 Tetanus Toxoid (Adsorbed) I.P Injectable suspension for intramuscular
use
Tetanus
6 Rabies Vaccine (SURE RAB) Intramuscular or intradermal route Rabies
7 Freeze Dried Measles Vaccine (live attenuated) Subcutaneous route Measles
8 Boostrix Intramuscular injection Diphtheria, pertussis &
tetanus
9 Cervarix Intramuscular Human papilloma virus
10 Rotavac Oral Rotavirus

15. Covid vaccine update 2023::

19. FLU VACCINE UPDATE 2023:
Flu vaccines for the U.S. 2023-2024 season will contain the following:
Egg-based vaccines
• an A/Victoria/4897/2022 (H1N1)pdm09-like virus; (Updated)
• an A/Darwin/9/2021 (H3N2)-like virus;
• a B/Austria/1359417/2021 (B/Victoria lineage)-like virus; and
• a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.
•Cell- or recombinant-based vaccines
• an A/Wisconsin/67/2022 (H1N1)pdm09-like virus; (Updated)
• an A/Darwin/6/2021 (H3N2)-like virus;
• a B/Austria/1359417/2021 (B/Victoria lineage)-like virus; and
• a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.

20. Dengue vaccine update 2023:
•The dengue vaccine CYD-TDV or Dengvaxia was approved by the US Food & Drug Administration in 2019, the first
dengue vaccine to get the regulatory nod in the US.
•The first dengue vaccine, Dengvaxia (CYD-TDV) by Sanofi Pasteur, was first licensed in December, 2015,
in Mexico.
• It has been registered for use in individuals 9-45 years of age living in endemic areas. CYD-TDV is a
live recombinant tetravalent vaccine based on the yellow fever 17d backbone and is registered as a 3-
dose vaccine given on a 0/6/12 month schedule.
•3 Vaccine trial ongoing in India.
•i) panacea biotec(b/o live weakened version of 4 D.SEROTYPE)
•ii) SII
•iii) ICMR with sun pharma(iactivated whole virus)-single dose for all 4 serotypes

21. Vaccine update(WHO 2023)
JE UPDATE:
4 main types of Japanese Encephalitis (JE) vaccines currently in use:
inactivated mouse brain-based vaccines, inactivated cell-based vaccines, live attenuated
vaccines, and live recombinant vaccines.
WHO updates recommendations on HPV vaccination schedule:
WHO recommends:
•A one or two-dose schedule for girls aged 9-14 years
•A one or two-dose schedule for girls and women aged 15-20 years
•Two doses with a 6-month interval for women older than 21 years

22. Malaria vaccine update 2023:
R21/Matrix-M
Oxford University developed the new three-dose vaccine with help from the Serum Institute of India.
It is more than 75% effective and that protection is maintained for at least another year with a
booster.
cost about $2 to $4
1st vaccine was Mosquirix and made by GSK, is only about 30% effective, requires four doses and
protection fades within months.

23. HEPATITIS VACCINE UPDATE:
HEPATITIS A:
Both inactivated and live attenuated hepatitis A vaccines are highly immunogenic and immunization will generate long-
lasting, possibly life-long, protection against hepatitis A in children as well as in adults.
WHO recommends that vaccination against hepatitis A virus be integrated into the national immunization schedule for
children aged 1 year or older.
HEPATITIS B:
Both monovalent and products with multiple antigens are highly immunogenic and vaccination in a series of three
doses will generate long-lasting, possibly life-long, protection against hepatitis B.
WHO recommends that all infants should receive their first dose of Hepatitis B vaccine as soon as possible after
birth, preferably within 24 hours. The birth dose should be followed by 2 or 3 doses to complete the primary
series.
WHO also recommends that all health care workers receive this vaccine to prevent the risk of Hepatitis B in health
care settings.

24. Hepatitis E:
Currently, there are no WHO pre-qualified vaccines against hepatitis E.
In 2011, the first vaccine to prevent hepatitis E infection was registered in China.
Hepatitis C:
Currently, there are no WHO pre-qualified vaccines against hepatitis E.

25. PIPLINE VACCINE(WHO 2023)

33. NATIONAL IMMUNIZATION SCHEDULE (NIS) FOR
INFANTS, CHILDREN AND PREGNANT WOMEN

35. References:
https://www.who.int/health-topics/vaccines-and-immunization
Serum Institute of India | Manufacturer of Vaccines & immuno-biologicals - GMP Vaccine
Manufacturer
ICMR Vaccine Portal | Indian Council of Medical Research | Government of India
Home :: National Center for Vector Borne Diseases Control (NCVBDC) (mohfw.gov.in)
https://www.frontiersin.org/articles/10.3389/fimmu.2020.583077/full
 https://doi.org/10.1016/ B978-0-12-801238-3.00006-4
Clin Exp Vaccine Res 2023;12:193-208 https://doi.org/10.7774/cevr.2023.12.3.193 pISSN 2287-
3651

38. THANK YOU....